CADvue® MRI review software and analysis solution, offers maximum functionality for facilitating the analysis of all available time points (ATP) colorized image maps and quantitative data. CADvue allows the user to create standard and customized reports that enable the radiologist to communicate time-sensitive breast and prostate MRI study results to referring physicians.
For digital mammography, iCAD will highlight:
- SecondLook® Premier Digital CAD system**, is the next generation in digital mammography CAD from iCAD. SecondLook Premier incorporates CAD lesion metrics to provide clinicians with insight into the system’s decision-making process. Built completely on digital datasets iCAD believes this product will improve density detection sensitivities and help lower the rate of false positives. It also includes a breast density assessment system.
- SecondLook® Digital Multivendor solution*, a license-based product designed to provide image analysis to hospitals and radiology facilities using several different OEM technologies for digital mammography.
For CT CAD solutions, iCAD will demonstrate:
- VeraLook™, iCAD’s revolutionary CAD solution for virtual colonoscopy (CTC). This solution is designed to aid radiologists in the detection of polyps during their review of CTC exams. Clinical evidence suggests that CAD for CTC will enhance radiologist effectiveness in interpreting CTC studies.*
Important presentations and conference sessions discussing the use of computer-aided detection (CAD) and other advanced image analysis solutions for the early detection of cancer will be available electronically. These include:
C-0302 – “Sensitivity of a Computer-Aided Detection System Applied to Full-Field Digital Mammography (FFDM) According to Mammographic Projection,” by P. Merino Rasillo, A. Vega Bolívar, S. Sánchez Gómez, E. Ortega García, P. Alonso Bartolomé, P. Muñoz Cacho; Santander/ES
C-0303 – “Utility of the Computer-Aided-Detection System Applied to Full-Field Digital Mammography (FFDM) in a Screening Population: Preliminary Results in a Prospective Study,” by S. Sanchez Gomez, P. Merino Rasillo, P. Alonso Bartolomé, E. Ortega Garcia, M. Sánchez Movellan, V. Alvarez de Eulate, M. Gutierrez Fuente, A. Vega Bolivar; Santander/ES
C-0305 – “Performance of a Computer-Aided Detection System Applied to Full-Field Digital Mammography (FFDM),” by P. Merino Rasillo, A. Vega Bolívar, S. Sánchez Gómez, E. Ortega García, P. Alonso Bartolomé, P. Muñoz Cacho; Santander/ES
C-0306 – “Performance of a Computer-Aided Detection System Applied to Full-Field Digital Mammography (FFDM) According to Breast Density,” by P. Merino Rasillo, A. Vega Bolívar, S. Sánchez Gómez, P. Alonso Bartolomé, E. Ortega García, P. Muñoz Cacho; Santander/ES
C-0307 – “Sensitivity of a Computer-Aided Detection System Applied to Full-Field Digital Mammography (FFDM) According to Histopathology and Tumor Size,” by P. Merino Rasillo, A. Vega Bolívar, S. Sánchez Gómez, P. Alonso Bartolomé, E. Ortega García, P. Muñoz Cacho; Santander/ES
C-0309 – “Effect of Breast Density on Computer-Aided Detection System (CAD) Applied to Screen-Film Mammography for Breast Cancer,” by S. Sanchez Gomez, M. Torres Tabanera, A. Vega Bolivar, M. Sainz Miranda, A. Baroja Mazo, M. Ruiz Diaz, P. Martinez-Miravete, E. Lag Asturiano; Santander/ES, Madrid/ES, Logroño/ES
C-0407 – “A Computer-Aided Detection System for the Detection of Breast Cancer by Mammographic Characteristics, Lesion Size and Histology,” by S. Sanchez Gomez, M. Torres Tabanera, A. Vega Bolivar, M. Sainz Miranda, A. Baroja Mazo, M. Ruiz Diaz, P. Martinez-Miravete, E. Lag Asturiano; Santander/ES, Madrid/ES, Logroño/ES
C-3295 – “What's the Control in Studies Measuring the Effect of Computer-Aided Detection (CAD) on Observer Performance?” by N. Obuchowski, M. Meziane, A. Dachman, M. Lieber, P. Mazzone, J. Hoffmeister; Cleveland, OH/US, Chicago, IL/US, Nashua, NH/US
All of these products will be featured at the iCAD booth, #206, Expo B.
* Only available internationally
** Works in progress
About iCAD, Inc.
iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography (film-based, digital radiography and computed radiography), Magnetic Resonance Imaging (MRI) and Computed Tomography (CT). Since receiving FDA approval for the Company’s first breast cancer detection product in 2002, more than 3,200 iCAD systems have been placed in healthcare practices worldwide. iCAD’s solutions aid in the early detection of the most prevalent cancers including breast and prostate, and in the future colon and lung cancer. For more information, call (877) iCADnow or visit www.icadmed.com.
For iCAD, contact Darlene Deptula-Hicks at 603-882-5200 x7944, or via email at ddeptula@icadmed.com
For Investor Relations, contact Anne Marie Fields of Lippert/Heilshorn & Associates at 212-838-3777 x6604 or via email at afields@lhai.com
For media inquiries, contact Liza Heapes of MS&L PR
at 617-369-8787 or via e-mail at liza.heapes@mslworldwide.com
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”, “likely”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.
